Key result
Administration of vernakalant hydrochloride for chemical cardioversion of non-valvular atrial fibrillation resulted in a rare occurrence of unstable accelerated 1:1 atrial flutter requiring emergent direct current cardioversion.
Why the study?
Vernakalant is used for chemical cardioversion of recent-onset non-valvular atrial fibrillation, but rare adverse arrhythmic consequences require clinical vigilance.
Case Report (n=1)
Clinicians must remain vigilant and prepared to treat rare consequences such as unstable 1:1 atrial flutter when administering vernakalant for atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Vigilance for 1:1 flutter remains essential during vernakalant use; this case report leaves open its incidence and predictors.
Vernakalant is an atrial-selective, multi-channel anti-arrhythmic that offers a safe alternative to traditional approaches to chemical cardioversion of recent-onset, non-valvular atrial fibrillation. This case report describes a very rare occurrence of unstable accelerated 1:1 atrial flutter during an attempted cardioversion of non-valvular atrial fibrillation using vernakalant hydrochloride that required emergent direct current cardioversion. This case report highlights the need for clinicians to remain vigilant and be prepared to treat rare consequences of vernakalant administration.
No takes yet. Share an insight, caveat, or question.
Stoneman et al. (2021) conducted a case report in Non-valvular atrial fibrillation (n=1). Vernakalant hydrochloride was evaluated on Occurrence of unstable accelerated 1:1 atrial flutter requiring emergent direct current cardioversion. Administration of vernakalant hydrochloride for chemical cardioversion of non-valvular atrial fibrillation resulted in a rare occurrence of unstable accelerated 1:1 atrial flutter requiring emergent direct current cardioversion.
Synapse has enriched 10 related papers. Consider them for comparative context: